Federal Register / Vol. 65, No. 233 / Monday, December 4, 2000 / Notices 75725

normal testis, Ewing’s sarcoma, alveolar

rhabdomyosarcoma, as well as breast

cancer and other cancers (e.g., lung

carcinoma, prostate adenocarcinoma,

ovarian carcinoma, pancreatic

adenocarcinoma, glioblastoma, etc.).

The largest open reading frame of the

XAGE–1 transcript encodes a putative

protein of 16.3 kD (p16) with a potential

transmembrane domain at the amino

terminus. In addition, the XAGE–1

transcript contains a second ATG in the

reading frame corresponding to residue

66, which would encode a 9 kD protein

(p9). In vitro transfection experiments

using 293T cells have revealed a 9 kD

protein. However, the size of the protein

expressed endogenously is not yet

known. XAGE–1 shares homology with

GAGE/PAGE proteins in the C-terminal

end.

The invention relates to the fact that

the XAGE–1 gene is expressed in a

number of human cancers, specifically:

prostate, pancreatic, and ovarian

cancers, as well as a large percentage of

breast and lung tumors. The protein p9

and p16, immunogenic fragments

thereof, analogs of these proteins, and

nucleic acids encoding these proteins,

fragments, or analogs, can be

administered to persons with XAGE–1

expressing cancers to raise or augment

an immune response to the cancer. The

invention further provides nucleic acid

sequences encoding the protein, as well

as expression vectors, host cells, and

antibodies to the proteins. Further, the

invention provides immunoconjugates

that comprise an antibody to p16 or to

p9, and an effector molecule, such as a

label, a radioisotope, or a toxin. The

invention also provides methods of

inhibiting the growth of XAGE–1

expressing cells by contacting them

with immunoconjugates of an anti-p9 or

p16 antibody and a toxic moiety. The

invention also provides kits for the

detection of p9 or p16 proteins in a

sample. The XAGE–1 gene and encoded

protein could be of value in the

development of a cancer diagnostic and

cancer immunotherapy.

The above mentioned invention is

available for licensing on an exclusive

or non-exclusive basis.

Dated: November 22, 2000.

Jack Spiegel,

Director, Division of Technology Development

& Transfer, Office of Technology Transfer.

[FR Doc. 00–30716 Filed 12–1–00; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Heart, Lung, and Blood

Institute; Notice of Closed Meeting

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meeting.

The meeting will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Heart, Lung,

and Blood Institute Special Emphasis Panel.

Date: December 1, 2000.

Time: 8 a.m. to 6 p.m.

Agenda: To review and evaluate grant

applications.

Place: Bethesda Holiday Inn, Bethesda, MD

20017.

Contact Person: Eric H Brown, Scientific

Review Administrator, Review Branch, Room

7204, Division of Extramural Affairs,

National Heart, Lung, and Blood Institute,

National Institutes of Health, Bethesda, MD

20892.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.233, National Center for

Sleep Disorders Research; 93.837, Heart and

Vascular Diseases Research; 93.838, Lung

Diseases Research; 93.839, Blood Diseases

and Resources Research, National Institutes

of Health, HHS)

Dated: November 22, 2000.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–30711 Filed 11–1–00; 8:45 am]

BILLING CODE 4140–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

National Institute of Diabetes and

Digestive and Kidney Diseases; Notice

of Closed Meetings

Pursuant to section 10(d) of the

Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice

is hereby given of the following

meetings.

The meetings will be closed to the

public in accordance with the

provisions set forth in sections

552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,

as amended. The grant applications and

the discussions could disclose

confidential trade secrets or commercial

property such as patentable material,

and personal information concerning

individuals associated with the grant

applications, the disclosure of which

would constitute a clearly unwarranted

invasion of personal privacy.

Name of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Special Emphasis, Panel, ZDK1 GRB–B(J3)M.

Date: December 4, 2000.

Time: 12:30 p.m. to 2:30 p.m.

Agenda: To review and evaluate grant

applications.

Place: 2 Democracy Plaza, 6707 Democracy

Blvd, Rm 645, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: Ned Feder, Scientific

Review Administrator, Review Branch, DEA

NIDDK, Room 645, 6707 Democracy

Boulevard, National Institutes of Health,

Bethesda, MD 20892, (301) 594–8890.

This notice is being published less than 15

days prior to the meeting due to the timing

limitations imposed by the review and

funding cycle.

Name: of Committee: National Institute of

Diabetes and Digestive and Kidney Diseases

Special Emphasis Panel, ZDK1 GRB–B(J2)S.

Date: December 15, 2000.

Time: 3 p.m. to 5 p.m.

Agenda: To review and evaluate grant

applications.

Place: 2 Democracy Plaza, 6707 Democracy

Blvd, Rm 645, Bethesda, MD 20892,

(Telephone Conference Call).

Contact Person: Ned Feder, Scientific

Review Administrator, Review Branch, DEA,

NIDDK, Room 645, 6707 Democracy

Boulevard, National Institutes of Health,

Bethesda, MD 20892, (301) 594–8890.

(Catalogue of Federal Domestic Assistance

Program Nos. 93.847, Diabetes,

Endocrinology and Metabolic Research;

93.848, Digestive Diseases and Nutrition

Research; 93.849, Kidney Diseases, Urology

and Hematology Research, National Institutes

of Health, HHS)

Dated: November 27, 2000.

Anna Snouffer,

Acting Director, Office of Federal Advisory

Committee Policy.

[FR Doc. 00–30708 Filed 12–1–00; 8:45 am]

BILLING CODE 4410–01–M